PHARVARIS NV

$15.80 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About PHARVARIS NV

Pharvaris B.V. operates as a clinical-stage company. The Company focuses on the discovery and development of novel oral B2-receptor antagonists for the treatment of patients. Pharvaris serves customers in the Netherlands and Switzerland.

Popular Stocks Price Change
Ford F
$15.7 0.44% 0.44%
Apple AAPL
$144.84 0.77% 0.77%
Bank of America BAC
$46.37 1.8% 1.8%
Wells Fargo WFC
$48.38 4.72% 4.72%
Virgin Galactic SPCE
$20.01 5.53% 5.53%
PG&E PCG
$11.2 2.28% 2.28%
Kosmos Energy KOS
$3.81 2.97% 2.97%
NIO NIO
$37.71 1.7% 1.7%
AMC AMC
$40.74 2.21% 2.21%

News

California Scrambles to Find Electricity to Offset Plant Closures
 Oct 2021
California Scrambles to Find Electricity to Offset Plant Closures
Musk Trolls Bezos Over Wealth. He Could Have Talked About Tesla Stock Outperforming Amazon.
 Oct 2021
Musk Trolls Bezos Over Wealth. He Could Have Talked About Tesla Stock Outperforming Amazon.
Dow Jones Futures: Microsoft, Tesla Rival Xpeng Are Buys In Broad Market Rally; Bitcoin ETF Launching
 Oct 2021
Dow Jones Futures: Microsoft, Tesla Rival Xpeng Are Buys In Broad Market Rally; Bitcoin ETF Launching

Connect

People who are active on baraka tribe community

Baraka Exchange Rules
Chat Guidelines
Affirm ($AFRM) Stock Discussion
DiDi ($DIDI) Stock Disussion

Stock Analysis

last close $15.8
1-mo return -9.4%
3-mo return 9.3%
avg daily vol. 7.47T
52-week high 42.86
52-week low 13.14
market cap. $512M
forward pe -
annual div. -
roe -43.2%
ltg forecast 8.1%
dividend yield -
annual rev. $--
inst own. 81.5%
baraka

Subscribe now for daily local and international financial news

Subscribe